HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Suzanne Ostrand-Rosenberg Selected Research

invariant chain (Ii-Key)

10/2015Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
11/2012Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
3/2010Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
10/2008Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
3/2008The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
2/2006Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
1/2006Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
2/2005Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
6/2004MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
3/2004Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Suzanne Ostrand-Rosenberg Research Topics

Disease

43Neoplasms (Cancer)
10/2015 - 08/2002
9Carcinoma (Carcinomatosis)
02/2014 - 08/2002
8Inflammation
01/2015 - 01/2006
5Melanoma (Melanoma, Malignant)
10/2015 - 03/2004
3Breast Neoplasms (Breast Cancer)
10/2015 - 01/2006
3Neoplasm Metastasis (Metastasis)
08/2012 - 05/2007
2Lung Neoplasms (Lung Cancer)
12/2010 - 10/2008
1Sarcoma (Soft Tissue Sarcoma)
10/2015
1Experimental Melanoma
08/2012
1Obesity
07/2011
1Leukemia
12/2010
1Large Cell Carcinoma
12/2010
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/2010

Drug/Important Bio-Agent (IBA)

14VaccinesIBA
10/2015 - 01/2004
11invariant chain (Ii-Key)IBA
10/2015 - 01/2004
7PeptidesIBA
11/2012 - 03/2004
6Neoplasm Antigens (Tumor Antigens)IBA
11/2012 - 01/2004
5AntigensIBA
11/2013 - 03/2004
5HLA-DR Antigens (HLA-DR)IBA
11/2012 - 03/2004
5Cancer VaccinesIBA
03/2008 - 01/2004
4Interleukin-6 (Interleukin 6)IBA
12/2014 - 10/2007
4Interleukin-10 (Interleukin 10)IBA
12/2014 - 07/2007
3Interleukin-12 (IL 12)IBA
12/2014 - 07/2007
3Proteins (Proteins, Gene)IBA
02/2014 - 10/2008
3Uveal melanomaIBA
06/2011 - 05/2007
3EpitopesIBA
02/2006 - 06/2004
2CytokinesIBA
12/2014 - 01/2006
2MHC class II transactivator proteinIBA
11/2012 - 01/2006
2InterleukinsIBA
08/2012 - 10/2007
2Adenocarcinoma of lungIBA
08/2012 - 06/2011
2Histocompatibility Antigens Class IIIBA
12/2010 - 03/2010
2Small Interfering RNA (siRNA)IBA
09/2009 - 01/2006
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
09/2009 - 05/2007
2Interferon-gamma (Interferon, gamma)IBA
09/2009 - 08/2002
2ArginaseIBA
10/2008 - 12/2005
2Interleukin-13IBA
12/2005 - 11/2002
1AntibodiesIBA
10/2015
1HMGB1 Protein (HMG1)IBA
10/2014
1ProteomeIBA
02/2014
1AshwagandhaIBA
11/2013
1withaferin AIBA
11/2013
1Immunoglobulin G (IgG)IBA
09/2013
1Indicators and Reagents (Reagents)IBA
11/2012
1HLA-DR7 Antigen (HLA DR7 Antigen)IBA
11/2012
1Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
08/2012
1Enzyme InhibitorsIBA
08/2012
1p38 Mitogen-Activated Protein KinasesIBA
08/2012
1Glucose (Dextrose)FDA LinkGeneric
07/2011
1Insulin (Novolin)FDA Link
07/2011
1Caspase 8 (Caspase-8)IBA
03/2011
1CaspasesIBA
03/2011
1Caspase 3 (Caspase-3)IBA
03/2011
1Proteasome Endopeptidase Complex (Proteasome)IBA
12/2010
1HLA-A Antigens (HLA-A)IBA
01/2010
1Prostaglandin E Receptors (Prostaglandin E Receptor)IBA
09/2009
1AH 23848IBA
09/2009
1L-SelectinIBA
07/2009
1Plasminogen Activators (Plasminogen Activator)IBA
07/2009
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
07/2009
1Toll-Like Receptor 4IBA
06/2009
1Complement System Proteins (Complement)IBA
12/2008
1Prostaglandins E (PGE)IBA
10/2008
1NF-kappa B (NF-kB)IBA
10/2008
1Interleukin-1 (Interleukin 1)IBA
10/2007
1gemcitabineFDA Link
07/2007
1Dinoprostone (PGE2)FDA Link
05/2007
14- (5- (4- chlorophenyl)- 3- (trifluoromethyl)- 1H- pyrazol- 1- yl)benzenesulfonamideIBA
05/2007
1Interleukin-1beta (Interleukin 1 beta)IBA
05/2007
1alpha-galactosylceramideIBA
12/2005
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
12/2005
1Nitric Oxide (Nitrogen Monoxide)FDA Link
11/2005
1Muramidase (Lysozyme)IBA
02/2005
1Isoantigens (Alloantigen)IBA
03/2004
1Tetanus Toxoid (Vaccine, Tetanus)FDA Link
03/2004
1STAT6 Transcription FactorIBA
02/2004
1Carbon MonoxideIBA
01/2004
1CarrageenanIBA
08/2002
1PerforinIBA
08/2002

Therapy/Procedure

15Immunotherapy
01/2015 - 01/2004
2Therapeutics
10/2015 - 01/2015
2Surgical Instruments (Clip)
12/2010 - 03/2010
1Transplantation (Transplant Recipients)
04/2004